GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Recommendation of “Buy” from Brokerages

GeoVax Labs, Inc. (NASDAQ:GOVX) has received a consensus rating of “Buy” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $13.25.

A number of equities analysts have issued reports on GOVX shares. EF Hutton Acquisition Co. I raised GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. Noble Financial raised their price objective on GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a research note on Monday, August 19th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Friday. Finally, Alliance Global Partners started coverage on shares of GeoVax Labs in a research note on Monday, November 11th. They issued a “buy” rating and a $15.00 price objective on the stock.

GeoVax Labs Stock Performance

GeoVax Labs stock opened at $2.43 on Monday. GeoVax Labs has a 1-year low of $1.09 and a 1-year high of $11.18. The stock’s fifty day moving average is $2.37 and its two-hundred day moving average is $2.60.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The firm had revenue of $2.79 million during the quarter, compared to analysts’ expectations of $1.84 million. During the same quarter last year, the company posted ($4.80) earnings per share. As a group, equities analysts forecast that GeoVax Labs will post -5.1 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.